FUS was initially identified as an oncofusion protein in human liposarcomas and later in other cancers where chromosomal rearrangements paired the FUS transactivation domain with transcription factors such as CHOP (Rabbitts et al. 1993; Crozat et al. 1993), CREB3L2 (Panagopoulos et al. 2004), and ERG (Shimizu et al. 1993). Here, FUS is linked to liposarcoma.